Terms: = Ovarian cancer AND BMPR1A, ACVRLK3, 657, ENSG00000107779, P36894, ALK3, CD292
53 results:
1. Genetic landscape of a large cohort of Primary ovarian Insufficiency: New genes and pathways and implications for personalized medicine.
Heddar A; Ogur C; Da Costa S; Braham I; Billaud-Rist L; Findikli N; Beneteau C; Reynaud R; Mahmoud K; Legrand S; Marchand M; Cedrin-Durnerin I; Cantalloube A; Peigne M; Bretault M; Dagher-Hayeck B; Perol S; Droumaguet C; Cavkaytar S; Nicolas-Bonne C; Elloumi H; Khrouf M; Rougier-LeMasle C; Fradin M; Le Boette E; Luigi P; Guerrot AM; Ginglinger E; Zampa A; Fauconnier A; Auger N; Paris F; Brischoux-Boucher E; Cabrol C; Brun A; Guyon L; Berard M; Riviere A; Gruchy N; Odent S; Gilbert-Dussardier B; Isidor B; Piard J; Lambert L; Hamamah S; Guedj AM; Brac de la Perriere A; Fernandez H; Raffin-Sanson ML; Polak M; Letur H; Epelboin S; Plu-Bureau G; Wołczyński S; Hieronimus S; Aittomaki K; Catteau-Jonard S; Misrahi M
EBioMedicine; 2022 Oct; 84():104246. PubMed ID: 36099812
[TBL] [Abstract] [Full Text] [Related]
2. Who are the long-term survivors of recurrent ovarian carcinoma?: a retrospective analysis of a multicenter study.
Yoshihara M; Mogi K; Kitami K; Uno K; Iyoshi S; Tano S; Fujimoto H; Miyamoto E; Yoshikawa N; Emoto R; Matsui S; Kajiyama H
Int J Clin Oncol; 2022 Oct; 27(10):1660-1668. PubMed ID: 35906336
[TBL] [Abstract] [Full Text] [Related]
3. Diagnostic Performance of the ovarian-Adnexal Reporting and Data System (O-RADS) Ultrasound Risk Score in Women in the United States.
Jha P; Gupta A; Baran TM; Maturen KE; Patel-Lippmann K; Zafar HM; Kamaya A; Antil N; Barroilhet L; Sadowski EA
JAMA Netw Open; 2022 Jun; 5(6):e2216370. PubMed ID: 35679042
[TBL] [Abstract] [Full Text] [Related]
4. Novel Interactive Tool for Breast and ovarian cancer Risk Assessment (Bright Pink Assess Your Risk): Development and Usability Study.
Hibler EA; Fought AJ; Kershaw KN; Molsberry R; Nowakowski V; Lindner D
J Med Internet Res; 2022 Feb; 24(2):e29124. PubMed ID: 35200148
[TBL] [Abstract] [Full Text] [Related]
5. Evaluation of Combined cancer Markers With Lactate Dehydrogenase and Application of Machine Learning Algorithms for Differentiating Benign Disease From Malignant ovarian cancer.
Jeong S; Son DS; Cho M; Lee N; Song W; Shin S; Park SH; Lee DJ; Park MJ
Cancer Control; 2021; 28():10732748211033401. PubMed ID: 34923833
[TBL] [Abstract] [Full Text] [Related]
6. Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR).
Trédan O; Provansal M; Abdeddaim C; Lardy-Cleaud A; Hardy-Bessard AC; Kalbacher E; Floquet A; Venat-Bouvet L; Lortholary A; Pop O; Frenel JS; Cancel M; Largillier R; Louvet C; You B; Zannetti A; Anota A; Treilleux I; Pissaloux D; Houlier A; Savoye AM; Mouret-Reynier MA; Meunier J; Levaché CB; Brocard F; Ray-Coquard I
Gynecol Oncol; 2022 Jan; 164(1):18-26. PubMed ID: 34696892
[TBL] [Abstract] [Full Text] [Related]
7. Anti-Müllerian hormone concentration regulates activin receptor-like kinase-2/3 expression levels with opposing effects on ovarian cancer cell survival.
Chauvin M; Garambois V; Choblet S; Colombo PE; Chentouf M; Gros L; De Brauwere DP; Duonor-Cerutti M; Dumas K; Robert B; Jarlier M; Martineau P; Navarro-Teulon I; Pépin D; Chardès T; Pèlegrin A
Int J Oncol; 2021 Jul; 59(1):. PubMed ID: 34013359
[TBL] [Abstract] [Full Text] [Related]
8. Fusion imaging in preoperative assessment of extent of disease in patients with advanced ovarian cancer: feasibility and agreement with laparoscopic findings.
Moro F; Bertoldo V; Avesani G; Moruzzi MC; Mascilini F; Bolomini G; Caliolo G; Esposito R; Moroni R; Zannoni GF; Fagotti A; Manfredi R; Scambia G; Testa AC
Ultrasound Obstet Gynecol; 2021 Dec; 58(6):916-925. PubMed ID: 33847427
[TBL] [Abstract] [Full Text] [Related]
9. Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast cancer or ovarian cancer, 2012-2019.
Kurian AW; Ward KC; Abrahamse P; Bondarenko I; Hamilton AS; Deapen D; Morrow M; Berek JS; Hofer TP; Katz SJ
J Clin Oncol; 2021 May; 39(15):1631-1640. PubMed ID: 33560870
[TBL] [Abstract] [Full Text] [Related]
10. Comparing 5-Year and Lifetime Risks of Breast cancer using the Prospective Family Study Cohort.
MacInnis RJ; Knight JA; Chung WK; Milne RL; Whittemore AS; Buchsbaum R; Liao Y; Zeinomar N; Dite GS; Southey MC; Goldgar D; Giles GG; Kurian AW; ; Andrulis IL; John EM; Daly MB; Buys SS; Phillips KA; Hopper JL; Terry MB
J Natl Cancer Inst; 2021 Jun; 113(6):785-791. PubMed ID: 33301022
[TBL] [Abstract] [Full Text] [Related]
11. Construction of a new tumor immunity-related signature to assess and classify the prognostic risk of ovarian cancer.
Ding J; Zhang Q; Chen S; Huang H; He L
Aging (Albany NY); 2020 Nov; 12(21):21316-21328. PubMed ID: 33154188
[TBL] [Abstract] [Full Text] [Related]
12. What Can Social Media Tell Us About Patient Symptoms: A Text-Mining Approach to Online ovarian cancer Forum.
Lee YJ; Park A; Roberge M; Donovan H
Cancer Nurs; 2022 Jan-Feb 01; 45(1):E27-E35. PubMed ID: 32649337
[TBL] [Abstract] [Full Text] [Related]
13. Treatment and outcomes of a Danish ovarian cancer population.
Berg T; Nøttrup TJ; Peen UBS; Roed H
Dan Med J; 2020 Jan; 67(1):. PubMed ID: 31908253
[TBL] [Abstract] [Full Text] [Related]
14. Considerations When Using Breast cancer Risk Models for Women with Negative BRCA1/BRCA2 Mutation Results.
MacInnis RJ; Liao Y; Knight JA; Milne RL; Whittemore AS; Chung WK; Leoce N; Buchsbaum R; Zeinomar N; Dite GS; Southey MC; Goldgar D; Giles GG; McLachlan SA; Weideman PC; Nesci S; Friedlander ML; Glendon G; ; Andrulis IL; John EM; Daly MB; Buys SS; Phillips KA; Hopper JL; Terry MB
J Natl Cancer Inst; 2020 Apr; 112(4):418-422. PubMed ID: 31584660
[TBL] [Abstract] [Full Text] [Related]
15. Analysis of polymorphisms in genes associated with the FA/BRCA pathway in three patients with multiple primary malignant neoplasms.
Wang L; Wang H; Wang T; Liu J; Chen W; Wang Y; Chen C; Zhu H; Dai P
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):1101-1112. PubMed ID: 30942098
[TBL] [Abstract] [Full Text] [Related]
16. A mathematical-descriptor of tumor-mesoscopic-structure from computed-tomography images annotates prognostic- and molecular-phenotypes of epithelial ovarian cancer.
Lu H; Arshad M; Thornton A; Avesani G; Cunnea P; Curry E; Kanavati F; Liang J; Nixon K; Williams ST; Hassan MA; Bowtell DDL; Gabra H; Fotopoulou C; Rockall A; Aboagye EO
Nat Commun; 2019 Feb; 10(1):764. PubMed ID: 30770825
[TBL] [Abstract] [Full Text] [Related]
17. Prevalence and characterization of ATM germline mutations in Chinese BRCA1/2-negative breast cancer patients.
Yang Z; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Zhang J; Xie Y
Breast Cancer Res Treat; 2019 Apr; 174(3):639-647. PubMed ID: 30607632
[TBL] [Abstract] [Full Text] [Related]
18. Survival of Women With Type I and II Epithelial ovarian cancer Detected by Ultrasound Screening.
van Nagell JR; Burgess BT; Miller RW; Baldwin L; DeSimone CP; Ueland FR; Huang B; Chen Q; Kryscio RJ; Pavlik EJ
Obstet Gynecol; 2018 Nov; 132(5):1091-1100. PubMed ID: 30303916
[TBL] [Abstract] [Full Text] [Related]
19. Trends in Place of Death Among Patients With Gynecologic cancer in the United States.
Hicks-Courant K; Melamed A; Worley MJ; Kim YB; Schorge JO; Rauh-Hain JA
Obstet Gynecol; 2018 Jun; 131(6):1111-1120. PubMed ID: 29742673
[TBL] [Abstract] [Full Text] [Related]
20. Clinicopathological and Prognostic Significance of cancer Stem Cell Markers in ovarian cancer Patients: Evidence from 52 Studies.
Tao Y; Li H; Huang R; Mo D; Zeng T; Fang M; Li M
Cell Physiol Biochem; 2018; 46(4):1716-1726. PubMed ID: 29730663
[TBL] [Abstract] [Full Text] [Related]
[Next]
